$6.13
1.13% today
Nasdaq, Feb 28, 04:52 pm CET
ISIN
US92539P1012
Symbol
VERV

Verve Therapeutics Inc Stock price

$6.20
-1.56 20.10% 1M
+0.68 12.32% 6M
+0.56 9.93% YTD
-11.34 64.65% 1Y
-26.45 81.01% 3Y
-25.72 80.58% 5Y
-25.72 80.58% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.11 1.74%
ISIN
US92539P1012
Symbol
VERV
Sector
Industry

Key metrics

Market capitalization $524.92m
Enterprise Value $56.26m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.31
P/S ratio (TTM) P/S ratio 21.51
P/B ratio (TTM) P/B ratio 1.03
Revenue growth (TTM) Revenue growth 219.91%
Revenue (TTM) Revenue $24.40m
EBIT (operating result TTM) EBIT $-226.54m
Free Cash Flow (TTM) Free Cash Flow $-162.06m
Cash position $539.92m
EPS (TTM) EPS $-2.46
P/E forward negative
P/S forward 23.92
EV/Sales forward 2.94
Short interest 18.69%
Show more

Is Verve Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Verve Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Verve Therapeutics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Verve Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Verve Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
24 24
220% 220%
100%
- Direct Costs 6.57 6.57
43% 43%
27%
18 18
556% 556%
73%
- Selling and Administrative Expenses 42 42
60% 60%
171%
- Research and Development Expense 196 196
12% 12%
804%
-220 -220
7% 7%
-902%
- Depreciation and Amortization 6.57 6.57
43% 43%
27%
EBIT (Operating Income) EBIT -227 -227
4% 4%
-928%
Net Profit -197 -197
2% 2%
-808%

In millions USD.

Don't miss a Thing! We will send you all news about Verve Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verve Therapeutics Inc Stock News

Neutral
GlobeNewsWire
one day ago
Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second quarter of 2025, with final dose escalation data in the second half of 2025
Neutral
GlobeNewsWire
25 days ago
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on January 31, 2025, the company granted equity awards to eight new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment wi...
Neutral
PRNewsWire
28 days ago
NEW YORK , Jan. 31, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Verve Therapeutics, Inc. (NASDAQ: VERV) breached their fiduciary duties to shareholders.  The investigation concerns potential self-dealing.
More Verve Therapeutics Inc News

Company Profile

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan, and Burt A. Adelman in 2018 and is headquartered in Cambridge, MA.

Head office United States
CEO Sekar Kathiresan
Employees 255
Founded 2018
Website www.vervetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today